CN114980892A - 用于治疗发作性睡病的tak-925 - Google Patents

用于治疗发作性睡病的tak-925 Download PDF

Info

Publication number
CN114980892A
CN114980892A CN202080073637.7A CN202080073637A CN114980892A CN 114980892 A CN114980892 A CN 114980892A CN 202080073637 A CN202080073637 A CN 202080073637A CN 114980892 A CN114980892 A CN 114980892A
Authority
CN
China
Prior art keywords
compound
subject
hours
hour
plasma concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080073637.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·哈特曼
R·伊文思
H·费塞尔
田中真一郎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN114980892A publication Critical patent/CN114980892A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080073637.7A 2019-09-13 2020-09-12 用于治疗发作性睡病的tak-925 Pending CN114980892A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962900298P 2019-09-13 2019-09-13
US62/900,298 2019-09-13
US202063031686P 2020-05-29 2020-05-29
US63/031,686 2020-05-29
PCT/IB2020/058483 WO2021048822A1 (en) 2019-09-13 2020-09-12 Tak-925 for use in treating narcolepsy

Publications (1)

Publication Number Publication Date
CN114980892A true CN114980892A (zh) 2022-08-30

Family

ID=72560858

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080073637.7A Pending CN114980892A (zh) 2019-09-13 2020-09-12 用于治疗发作性睡病的tak-925

Country Status (11)

Country Link
US (1) US20220339143A1 (https=)
EP (1) EP4028004A1 (https=)
JP (1) JP2022547711A (https=)
KR (1) KR20220062012A (https=)
CN (1) CN114980892A (https=)
AU (1) AU2020346456A1 (https=)
BR (1) BR112022004587A2 (https=)
CA (1) CA3154321A1 (https=)
CO (1) CO2022004596A2 (https=)
MX (1) MX2022003018A (https=)
WO (1) WO2021048822A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004576A2 (pt) * 2019-09-13 2022-06-14 Takeda Pharmaceuticals Co Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica
MX2022008392A (es) 2020-01-10 2022-08-08 Takeda Pharmaceuticals Co Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
BR112023020104A2 (pt) * 2021-04-02 2023-11-14 Takeda Pharmaceuticals Co Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides
CN119677753A (zh) 2022-04-22 2025-03-21 帝人制药株式会社 氧杂氮杂环庚三烯衍生物
AR130709A1 (es) 2022-10-07 2025-01-08 Kissei Pharmaceutical Compuesto de ciclopentano
WO2024095158A1 (en) * 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
TW202535890A (zh) 2023-10-20 2025-09-16 日商帝人製藥股份有限公司 氧氮呯衍生物之結晶或其溶劑合物之結晶
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2025229493A1 (en) * 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107810006A (zh) * 2014-10-23 2018-03-16 卫材R&D管理有限公司 用于治疗失眠的组合物和方法
CN108884043A (zh) * 2016-02-04 2018-11-23 武田药品工业株式会社 取代的哌啶化合物及其用途
CN109562085A (zh) * 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107810006A (zh) * 2014-10-23 2018-03-16 卫材R&D管理有限公司 用于治疗失眠的组合物和方法
CN109562085A (zh) * 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
CN108884043A (zh) * 2016-02-04 2018-11-23 武田药品工业株式会社 取代的哌啶化合物及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHAEL D. CABANA主编: "《儿科5分钟速查》", 30 April 2017, 上海科学技术出版社, pages: 157 - 158 *
SUZUKI M ET AL.: ""AN OREXIN 2 RECEPTOR-SELECTIVE AGONIST TAK-925 AMELIORATES NARCOLEPSY-LIKE SYMPTOMS IN OREXIN/ATAXIN-3 MICE"", 《SLEEP》, vol. 41, pages 1 *

Also Published As

Publication number Publication date
BR112022004587A2 (pt) 2022-06-14
KR20220062012A (ko) 2022-05-13
US20220339143A1 (en) 2022-10-27
WO2021048822A1 (en) 2021-03-18
CO2022004596A2 (es) 2022-08-30
AU2020346456A1 (en) 2022-04-14
CA3154321A1 (en) 2021-03-18
EP4028004A1 (en) 2022-07-20
MX2022003018A (es) 2022-06-14
JP2022547711A (ja) 2022-11-15

Similar Documents

Publication Publication Date Title
CN114980892A (zh) 用于治疗发作性睡病的tak-925
US20220331303A1 (en) Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
TWI298254B (en) Use of optically pure (s,s) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome
JP2003503450A5 (https=)
JP2025510916A (ja) 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
JP2025510295A (ja) 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン
ITRM970365A1 (it) Composizione riequilibratrice delle turbe dell'umore in individui sani
US11897875B2 (en) Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type a receptors as fast acting treatment for depression and mood disorders
WO2024160389A1 (en) 5-methoxy-n,n-dimethyltryptamine for use in the treatment of mental disorders in breastfeeding mothers
CN1541092A (zh) 治疗原发性失眠的方法
CN1395487A (zh) 米氮平用于治疗睡眠障碍的用途
US20200360398A1 (en) Methods for treating hypersomnia
TW202302100A (zh) 食慾激素２受體促效劑於治療食慾激素介導之疾病或病症之用途
JP2005132799A (ja) 本態性振戦の予防・治療剤
US20090306050A1 (en) Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
US20110092486A1 (en) Ih channel inhibitors for the promotion of wakefulness
HK40105808A (zh) 美维达林和其他d1正向别构调节剂在幻觉和痴呆相关精神病的治疗中的用途
Juncos Perioperative management of patients with Parkinson’s disease
EP2266554A1 (en) Method of treating sleep disorders using eplivanserin
EP2186511A1 (en) Method of treating sleep disorders using eplivanserin
EP2435044A1 (en) Method of treating sleep disorders using the combination of eplivanserin and zolpidem

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220830

WD01 Invention patent application deemed withdrawn after publication